Motus GI Holdings Inc. priced its IPO of 3.5 million shares at $5 apiece.
The medical technology company also granted underwriters an option to buy an additional 525,000 common shares in the offering.
Motus GI initially intended to sell 4,250,000 common shares in the IPO.
The company's shares are expected to start trading on the Nasdaq Capital Market under the MOTS symbol Feb. 14.
Closing of the IPO is expected to occur Feb. 16, subject to customary closing conditions.
Piper Jaffray & Co. is acting as the sole book-running manager in the offering, with Oppenheimer & Co. as lead manager.